H.C. Wainwright lowered the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $30 and keeps a Buy rating on the shares. The firm updated the company’s model post the earnings report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics Reports Q2 2025 Progress and Financials
- Intellia Therapeutics: Strategic Advancements and Promising Clinical Trials Justify Buy Rating
- Intellia Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
- Intellia Therapeutics price target lowered to $21 from $25 at RBC Capital
- Intellia Therapeutics Announces Executive Retirement